Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LOW-DOSE INTEGRATED CHEMOIMMUNOHORMONOTHERAPY WITH CISPLATIN, SUBCUTANEOUS INTERLEUKIN-2, ALPHA-INTERFERON AND TAMOXIFEN FOR ADVANCED METASTATIC MELANOMA - A PILOT-STUDY
Autore:
BERNENGO MG; DOVEIL GC; BERTERO M; QUAGLINO P; FIERRO MT; SAVOIA P; APPINO A; COLONNA S;
Indirizzi:
UNIV TURIN,DERMATOL CLIN,VIA CHERASCO 23 I-10126 TURIN ITALY
Titolo Testata:
Melanoma research
fascicolo: 3, volume: 6, anno: 1996,
pagine: 257 - 265
SICI:
0960-8931(1996)6:3<257:LICWCS>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER CELLS; MALIGNANT-MELANOMA; CANCER-PATIENTS; COMBINATION CHEMOTHERAPY; NATURAL-KILLER; DACARBAZINE; THERAPY; INVIVO; ALFA-2A; CHEMOIMMUNOTHERAPY;
Keywords:
CHEMOTHERAPY; CISPLATIN; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-2 THERAPEUTIC USE; MELANOMA THERAPY; TAMOXIFEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
M.G. Bernengo et al., "LOW-DOSE INTEGRATED CHEMOIMMUNOHORMONOTHERAPY WITH CISPLATIN, SUBCUTANEOUS INTERLEUKIN-2, ALPHA-INTERFERON AND TAMOXIFEN FOR ADVANCED METASTATIC MELANOMA - A PILOT-STUDY", Melanoma research, 6(3), 1996, pp. 257-265

Abstract

Recently, Khayat et al. reported that high-dose recombinant interleukin-2 (rIL-2) i.v. may induce tumour regressions in metastatic melanomapatients through an association with cisplatin (CDDP) and alpha-interferon (alpha-IFN), Treatment-related toxicities are, however, important, Previous studies have demonstrated that rIL-2 toxicity may be reduced through a subcutaneous injection. In order to evaluate the effectiveness of low subcutaneous rIL-2 doses in a chemoimmuno-hormonotherapeutic combination, 36 metastatic melanoma patients were treated with CDDP, rIL-2, alpha-IFN end tamoxifen (TAM). The overall response rate was47.2%: five patients had complete response (14%), 12 partial response(33%) and 13 stable disease (36%). Median response duration was 6.4 months (range: 2-29+). Median overall survival was 10 months (range: 3-36+). The CDDP/rlL-2/alpha-IFN/TAM regimen was effective both on soft tissue and visceral metastases, Toxicity was low and patient management did not require an intensive care unit, A statistically significant increase in both percentage and absolute values of lymphocytes, eosinophils, CD3+/CD4+, CD25+, CD16/56+ and HLA-DR+ cells was found in all patients after two treatment courses, This study shows that lower dosesof subcutaneous rIL-2, as well as CDDP and alpha-IFN, associated withTAM, may have similar anticancer efficacy with respect to Khayat's schedule but lower toxicity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 14:20:34